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Introduction: Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology,
characterized by a triad of vascular injury, autoimmunity and tissue ﬁbrosis. It is known that
a  positive family history is the greatest risk factor already identiﬁed for the development of
SSc  in a given individual. Preliminary observation of a high prevalence of polyautoimmunity
and  of familial autoimmunity in SSc patients support the idea that different autoimmune
phenotypes may share common susceptibility variants.
Objectives: To describe the frequency of familial autoimmunity and polyautoimmunity in
60  SSc patients in the Midwest region of Brazil, as well as to report the main autoimmune
diseases observed in this association of comorbidities.
Methods: A cross-sectional study with recruitment of 60 consecutive patients selected at
the  Rheumatology Department, University Hospital, Medicine School, Federal University of
Mato Grosso do Sul (FMUFMS), as well as interviews of their relatives during the period from
February 2013 to March 2014.
Results: A frequency of 43.3% of polyautoimmunity and of 51.7% of familial autoimmunity
in  SSc patients was found. Patients with the presence of polyautoimmunity and famil-
ial  autoimmunity presented primarily the diffuse form of SSc, but this indicator did not
reach statistical signiﬁcance. The autoimmune diseases most frequently observed in polyau-
toimmunity patients were: Hashimoto’s thyroiditis (53.8%), Sjögren’s syndrome (38.5%), andinﬂammatory myopathy (11.5%). The main autoimmune diseases observed in SSc patients’
relatives were: Hashimoto’s thyroiditis (32.3%), rheumatoid arthritis (22.6%), and SLE (22.6%).
The  presence of more than one autoimmune disease in SSc patients did not correlate with
disease severity or activity.
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Conclusions: From the high prevalence of coexisting autoimmune diseases found in SSc
patients, we stress the importance of the concept of shared autoimmunity, in order to pro-
mote a continued vigilance and promptly diagnose other possible autoimmune disease in
patients, or in their kin.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Autoimunidade  familial  e  poliautoimunidade  em  60  pacientes  portadores
de  esclerose  sistêmica  da  região  Centro-Oeste  do  Brasil
Palavras-chave:
Autoanticorpos
Esclerose sistêmica
Doenc¸a autoimune
Poliautoimunidade
Autoimunidade familiar
r  e  s  u  m  o
Introduc¸ão: A esclerose sistêmica (ES) é uma enfermidade do tecido conjuntivo de etiolo-
gia  desconhecida, caracterizada pela tríade de injúria vascular, autoimunidade e ﬁbrose
tecidual. Sabe-se que uma história familiar positiva representa o maior fator de risco já iden-
tiﬁcado para o desenvolvimento da ES em um determinado indivíduo. Observac¸ão prévia
de  alta prevalência de poliautoimunidade e de autoimunidade familiar em pacientes com
ES,  reforc¸a a ideia de que fenótipos autoimunes distintos podem dividir variantes comuns
de  susceptibilidade.
Objetivos: Descrever a frequência de autoimunidade familiar e de poliautoimunidade em 60
pacientes com ES da região Centro Oeste do Brasil, bem como relatar as principais doenc¸as
autoimunes observadas nesta associac¸ão de comorbidades.
Métodos: Realizou-se um estudo transversal com recrutamento de 60 pacientes consecu-
tivos, selecionados no Servic¸o de Reumatologia do Hospital Universitário da Faculdade de
Medicina da Universidade Federal de Mato Grosso do Sul (FMUFMS), bem como entrevista
de  seus parentes, durante o período de fevereiro de 2013 a marc¸o de 2014.
Resultados: Foi encontrada uma frequência de 43,3% de poliautoimunidade e de 51,7%
de  autoimunidade familiar nos pacientes com ES. Os pacientes com presenc¸a de poliau-
toimunidade e de autoimunidade familiar eram principalmente da forma difusa de ES,
porém este índice não atingiu signiﬁcância estatística. As doenc¸as autoimunes mais comu-
mente observadas nos pacientes com poliautoimunidade foram: tireoidite de Hashimoto
(53,8%), síndrome de Sjögren (38,5%) e miopatia inﬂamatória (11,5%). As principais doenc¸as
autoimunes observadas nos parentes dos pacientes com ES foram: tireoidite de Hashimoto
(32,3%), artrite reumatóide (22,6%) e LES (22,6%). A presenc¸a de mais de uma  enfermidade
autoimune em pacientes com ES não se correlacionou com maior gravidade ou atividade da
doenc¸a.
Conclusões: A partir da alta prevalência encontrada de doenc¸as autoimunes coexistentes em
pacientes com ES, salientamos a importância do conceito de autoimunidade compartilhada,
de  forma a promover uma vigilância constante e diagnosticar prontamente uma possível
outra doenc¸a autoimune nos pacientes ou em seus familiares.
© 2016 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC
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ystemic sclerosis (SSc) is a disease of the connective tissue
ith an autoimmune character, and with extreme heterogene-
ty in its clinical presentation, with involvement of multiple
ystems and following a varied and unpredictable course.1 Its
tiology remains unknown, and a multifactorial cause is sug-
ested; possibly SSc is triggered by environmental factors in a
enetically predisposed individual.2
The hallmark of SSc is the occurrence of microvascu-
opathy, ﬁbroblast activation and an excessive production
f collagen.3 This is a unique condition, because it displays
eatures of three distinct pathophysiological processes, the
o-called triad of vascular injury, autoimmunity (cellular
nd humoral), and tissue ﬁbrosis, leading to cutaneousBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
involvement, besides affecting multiple internal organs, for
instance, lungs, heart and gastrointestinal tract, as well as
musculoskeletal manifestations.3,4
The genetic component of autoimmune diseases is repre-
sented by the increased risk of developing SSc in twin brothers
of affected individuals.3,4 Basically, SSc is not a genetic dis-
order, but there is consensus that, actually, the disease has
a genetic component based on reports of monozygotic twins
with a propensity to SSc.5
In 1953, Rees and Bennett6 described the ﬁrst case of local-
ized scleroderma in a father and his daughter. Later, several
reports of familial scleroderma in different populations and
family relationships were published.2,5,7 Moreover, an associ-
ation between HLA and SSc has been described.5,8,9
A positive family history is the greatest risk factor ever
identiﬁed for the development of SSc in a given individual.8,10
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However, the low frequency of concordance rate of autoim-
mune diseases among siblings versus monozygotic twins
favors the presence of multiple genes contributing to a genetic
predisposition, including SSc.11
Hudson et al. used the term “autoimmunity kaleidoscope”
in reference to SSc patients to describe the fact that more
than one different autoimmune disease may coexist in a sin-
gle patient (polyautoimmunity) or in the same household
(familial autoimmunity).12 The high prevalence of polyau-
toimmunity (38%) as well as of familial autoimmunity (36%)
in SSc patients reinforces the idea that clinically distinct
autoimmune phenotypes may share common susceptibility
variants.12
Objectives
In this study, we  aim to describe the frequency of familial
autoimmunity and polyautoimmunity in 60 SSc patients living
in the Midwest region of Brazil, to report the main autoim-
mune diseases observed in this association of comorbidities,
and also to evaluate if the presence of more  than one autoim-
mune disease in SSc patients is associated with an increase of
disease activity or severity.
Methods
This is an observational, cross-sectional study.
Sixty consecutive patients were seen and selected at
the Rheumatology Department, University Hospital, Medicine
School, Federal University of Mato Grosso do Sul (FMUFMS)
during the period from February 2013 to March 2014.
To participate in this study, the patients should meet the
following criteria:
– Comply with the new 2013 classiﬁcation criteria for SSc13;
– In the absence of skin thickening, the patients should com-
ply with LeRoy and Medsger14 criteria for early-onset SSc.
– All patients who had other associated infectious diseases or
malignancies were excluded.
The study was approved by the Ethics Committee on
Research of the Federal University of Mato Grosso do Sul (opin-
ion CAAE: 31442614.3.0000.0021).
Polyautoimmunity was deﬁned as the occurrence of any
other autoimmune disease observed in patients with systemic
sclerosis. Familial autoimmunity was deﬁned as the occur-
rence of any other autoimmune disease affecting ancestors
(grandparents, mother, father by blood) or blood descendant
relatives (daughters, sons, granddaughters, grandsons) rela-
tives, or second- (sisters, brothers) or third- (aunts, uncles,
nieces and nephews) degree collateral SSc patients’ relatives.
To conﬁrm the illnesses associated with SSc patients or
with their families, the following criteria were used:– For systemic lupus erythematosus (SLE): compliance with
the new SLE classiﬁcation criteria (2012 of the Systemic
Lupus International Collaborating Clinics (SLICC) for lupus
derivation and validation.15 0 1 6;5 6(4):314–322
– Sjögren’s syndrome (SS): the diagnosis was based on the
American College of Rheumatology (ACR) criteria of 2012.16
– Rheumatoid arthritis (RA): RA classiﬁcation criteria of
ACR/EULAR 2010.17
– Psoriasis: diagnosis based on clinical criteria18 and, when
necessary, on a histopathological study.
– Pemphigus: clinical criteria were used18 through cytologi-
cal analysis, histopathological study and/or immunological
tests for detection of antiepithelial antibodies.
– Vitiligo: clinical criteria were used:18 history and physical
examination, as well as Wood lamp technique.
– Spondyloarthritis: new classiﬁcation criteria (2011) for axial
and peripheral espondiloartritrites by ASAS (Assessment on
Spondyloarthritis International Society) group were used.19
– Crohn’s disease: criteria from the American College of Gas-
troenterology’s Practice Parameter Committee 2001.20
– Antiphospholipid syndrome: criteria from the international
consensus (2006) for updating antiphospholipid syndrome
classiﬁcation and deﬁnition.21
– Hashimoto’s thyroiditis: the diagnosis was based on
the presence of anti-thyroid peroxidase and/or anti-
thyroglobulin antibodies in association with thyroid
parenchyma ultrasonographic changes compatible with
thyroiditis.22
– Diabetes mellitus type 1: criteria of the American Diabetes
Association, based on glycated hemoglobin, fasting glucose,
oral glucose tolerance test and classic symptoms of hyper-
glycemia, revised in 2010.23
– Mixed connective tissue disease (MCTD): criteria of Alarcon-
Segovia, 1989.24
– Inﬂammatory myopathy: Bohan and Peter criteria, 1975.25
– Localized scleroderma: the diagnosis was based mainly on
visual examination, taking into account the characteristics
commonly observed in skin lesions, plus a skin biopsy con-
sistent with increased collagen deposits.18
We  obtained the information necessary for a sociodemo-
graphic and clinical characterization of the disease through
an analysis of the medical records of each patient, with com-
pletion by patient interviews. At the ﬁrst visit, demographic
and clinical data were collected, including disease duration,
year of diagnosis, Rodnan skin score (modiﬁed),26 autoanti-
body tests, a full clinical examination, and current treatment.
Subsequently, all patients were evaluated and interviewed
with respect to all family members, in order to conﬁrm the
occurrence of other autoimmune diseases.
At the initial evaluation of the patient, we  collected spe-
ciﬁc data on Medsger severity criteria,27 Valentini criteria for
disease activity28 and Scleroderma Health Assessment Ques-
tionnaire (sHAQ).29
In our study, we used sera from patients previously
selected. The samples were properly frozen to −50 ◦C and
stored in the laboratory at the University Hospital of UFMS.
a. Antinuclear antibodies (ANA) – an indirect immunoﬂuores-used as substrate (Faar technique). The II Brazilian Consen-
sus on Antinuclear Factor in Hep-2 cells (2003) criteria30
were used in the interpretation of our ﬁndings.
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cal data and monitoring index in patients with and without
familial autoimmunity are presented in Table 4.
The time elapsed after the diagnosis of the disease
among polyautoimmunity patients (11.27 ± 1.27 years) was
Table 1 – Diseases most frequently observed among
polyautoimmunity patients and among SSc patients’
relatives and familial autoimmunity.
Variable n (%)
Polyautoimmunity (n = 26)
Hashimoto’s thyroiditis 14 (53.8)
Sjögren’s syndrome 10 (38.5)
Inﬂammatory myopathy 3 (11.5)
Type 1 Diabetes mellitus 3 (11.5)
APS 2 (7.7)
Rheumatoid arthritis 1 (3.8)
Crohn disease 1 (3.8)
Psoriasis 1 (3.8)
Familial autoimmunity (n = 31)
Hashimoto’s thyroiditis 10 (32.3)
Rheumatoid arthritis 7 (22.6)
SLE 7 (22.6)
Systemic sclerosis 5 (16.1)
Type 1 Diabetes mellitus 3 (9.7)
Scleroderma 2 (6.5)
Sjögren’s syndrome 2 (6.5)
Vitiligo 2 (6.5)
Crohn’s disease 1 (3.2)
MCTD 1 (3.2)
Pemphygus 1 (3.2)r e v b r a s r e u m a t o l
Sera were considered positive with a title ≥160 and diluted
to obtain ﬂuorescence negativity.
Sera were considered positive with a title ≥160 and diluted
until a negative result of ﬂuorescence has been obtained.
. Anti-Sm, anti-RNP, anti-Jo1, anti-Ro (SSA) and anti-La (SSB)
test – enzyme-linked immunosorbent assay (ELISA) tech-
nique was used, as previously described by McClain;31
speciﬁc kits were used as substrate for each test, according
to the manufacturer’s speciﬁcations (Hemagen Diagnos-
tics, Inc.). We  considered a positive result for the sample
when the value found was ≥3-fold greater than the cutoff
point.
c. Rheumatoid Factor test – nephelometry technique was
used; the sample was considered positive with a title
>40 IU/ml.
. Anti-thyroglobulin and anti-thyroid peroxidase tests – a
chemiluminescent microparticle immunoassay technique
was used according to the manufacturer’s instruc-
tions (Abbott ARCHITECT anti-Tg and anti-TPO, chemi-
luminescent microparticle immunoassay for quantitative
determination of autoantibodies of IgG class anti-
thyroglobulin and thyroid peroxidase in human serum and
plasma). For anti-thyroglobulin, the test was considered as
non-reactive if <40.0 IU/ml, and as reactive if >40.0 IU/ml.
For anti-thyroid peroxidase, the test was considered as
non-reactive if <35.0 IU/ml, and as reactive if >35.0 IU/ml.
e. Anticentromere test – indirect immunoﬂuorescence tech-
nique, with HEp2 cells as substrate, according to the II
Brazilian Consensus on Antinuclear Factor in Hep-2 cells
(2003) criteria30 for interpretation of results.
f. Anti-DNA topoisomerase 1 (anti-Scl70) test – an enzymatic
immunoassay technique32 was used with the speciﬁc kit
QUANTA Lite TM Scl-70 from INOVA Laboratory (INOVA
Diagnostics, Inc., San Diego, CA, USA), according to the
manufacturer’s speciﬁcations. The test was considered as
non-reactive if <20 units; weakly reactive if between 20 and
39 units; moderately reactive if between 40 and 80 units;
and highly reactive (high values) if >80 units.
. Anti-RNA polymerase III antibody – ELISA was used as pre-
viously described33 with the speciﬁc kit QUANTA Lite RNA
Pol III ELISA INOVA Laboratory (INOVA Diagnostics, Inc.,
San Diego, CA, USA), according to the manufacturer’s spec-
iﬁcations. The test was considered as non-reactive if <20
units; weakly reactive if between 20 and 39 units; moder-
ately reactive if between 40 and 80 units; and highly reactive
(high values) if >80 units.
tatistical  analysis
he comparison between patients with and without polyau-
oimmunity and familial autoimmunity, with respect to the
uantitative variables evaluated in this study, was carried out
sing Student’s t test. The chi-squared test was used to assess
he association between the presence or absence of polyau-
oimmunity and familial autoimmunity with the qualitative
ariables measured in this study. The results of the other vari-
bles assessed in this study were presented in the form of
escriptive statistics, or in tables and graphs. Statistical anal-
sis was performed using the software SPSS, version 20.0, and
 5% signiﬁcance level was considered. 6;5 6(4):314–322 317
Results
Table 1 shows, in descending order, the diseases observed
among polyautoimmunity patients, and among patients’ rela-
tives in whom familial autoimmunity was diagnosed. The
most frequent illnesses among patients with polyautoimmu-
nity were Hashimoto’s thyroiditis (n = 14–53.8%), Sjögren’s dis-
ease (n = 10–35.8%) and inﬂammatory myopathy (n = 3–11.5%).
On the other hand, the most frequent autoimmune diseases
observed in SSc patients’ relatives were Hashimoto’s thyroidi-
tis (n = 10–32.3%), rheumatoid arthritis (n = 7–22.6%) and SLE
(n = 7–22.6%).
Table 2 shows the number of concomitant autoimmune
diseases in SSc patients. The vast majority (n = 19–73.08%) of
patients had only one autoimmune disease associated with
SSc. Among patients with two other autoimmune diseases
concomitantly with SSc (n = 6–23.08%), one of these was always
Hashimoto’s thyroiditis, and the other autoimmune diseases
were: 3 patients also with Sjögren’s syndrome, one patient
with polymyositis, 1 patient with psoriasis, and 1 patient with
type 1diabetes. Only one (3.84%) patient (a woman) had more
than three concomitant diseases (SSc, Sjögren’s syndrome,
Hashimoto’s thyroiditis, and polymyositis).
The results regarding epidemiological data and monitor-
ing index in patients with and without polyautoimmunity are
shown in Table 3, while the results regarding epidemiologi-Spondyloarthritis 1 (3.2)
MCTD, mixed connective tissue disease.
The results are presented in absolute frequency (relative frequency).
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Table 2 – Number of concurrent autoimmune diseases in
patients with a diagnosis of systemic sclerosis (n = 26).
Number of other concurrent diseases n (%)
1 19 (73.08)
2 6 (23.08)
≥3 1 (3.84)
included.12,39,40The results are presented in absolute frequency (relative frequency).
signiﬁcantly greater than this time for patients without
polyautoimmunity. On the other hand, we  found no other
signiﬁcant difference between patients with and without
polyautoimmunity, with respect to other quantitative and
qualitative variables.
No signiﬁcant difference between patients with and with-
out familial autoimmunity was observed in relation to
quantitative or qualitative variables.
Tables 5 and 6 present, respectively, distributions of
patients with or without polyautoimmunity and with or with-
out familial autoimmunity in relation to results of laboratory
tests. It was observed that the percentage of polyautoim-
munity patients positive for anti-Ro antibody (n = 6–23.1%)
was signiﬁcantly higher than that of those patients without
polyautoimmunity (n = 1–2.9%; p = 0.016). No other statistical
signiﬁcance was found between the presence or absence of
polyautoimmunity and familial autoimmunity.
Table 3 – Epidemiological data and monitoring index in patient
Variable Polya
Yes (n = 26) 
Epidemiological data
Age 52.50 ± 2.12 
Gender
Male 0 (0.0) 
Female 26 (100.0) 
Race
Caucasian 14 (53.8) 
Brown 12 (46.2) 
Afro-descendent 0 (0.0) 
Diagnosis time
<5 years 6 (23.1) 
5–10 years 9 (34.6) 
>10 years 11 (42.3) 
Pre-diagnosis FRy time 3.19 ± 1.20 
Disease time after diagnosis 11.27 ± 1.27 
Clinical form
Limited 9 (34.6) 
Diffuse 10 (38.5) 
Recent onset 3 (11.5) 
Overlap 4 (15.4) 
Monitoring indexes
sHAQ 0.68 ± 0.08 
Severity scale 5.31 ± 0.60 
Activity scale 2.31 ± 0.30 
Skin score 13.92 ± 1.39 
The results are presented as mean ± mean standard error, or as absolute f
a p-Value in Student’s t test or chi-squared test. 0 1 6;5 6(4):314–322
In this study, the percentage of polyautoimmunity patients
with a positive anticentromere antibody (n = 9–29.0%) was sig-
niﬁcantly lower versus patients without polyautoimmunity
(n = 16–55.2%; p = 0.040). However, no association was found
between the presence or absence of familial autoimmunity
and the result for other autoantibodies.
Discussion
The coexistence of several autoimmune diseases in SSc
patients (polyautoimmunity) is well established.12,34–38 The
aggregation of various autoimmune diseases in families of SSc
patients is being also increasingly recognized.12,36,37,39
Many genetic factors that confer susceptibility to SSc
were recently identiﬁed and are primarily related to genes
coding for proteins responsible for transduction of signals
that comprise autoimmunity pathways common to many
diseases.12,39–41 In this group, polymorphisms related to
innate immunity pathways (IRF5), activation and differen-
tiation of T lymphocytes (STAT4, PTPN22) and autoimmune
intracellular signaling pathways (BANK1, BLK, TNFAIP3) areThe fact that most of these susceptibility factors have
been identiﬁed in other autoimmune diseases support the
existence of genetic overlapping between SSc and other
s with or without polyautoimmunity.
utoimmunity p-Value
No (n = 34)
50.18 ± 2.24 0.466
1 (2.9) 0.378
33 (97.1)
16 (47.1) 0.295
15 (44.1)
3 (8.8)
10 (29.4) 0.053
19 (55.9)
5 (14.7)
4.12 ± 1.27 0.608
7.76 ± 0.93 0.026a
17 (50.0) 0.634
10 (29.4)
4 (11.8)
3 (8.8)
0.60 ± 0.07 0.492
4.53 ± 0.47 0.307
2.37 ± 0.22 0.868
12.44 ± 1.54 0.491
requency (relative frequency).
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Table 4 – Epidemiological data and monitoring index in patients with or without familial autoimmunity.
Variable Familial  autoimmunity p-Value
Yes (n = 31) No (n = 29)
Epidemiological data
Age 54.00 ± 2.02 48.17 ± 2.31 0.062a
Gender
Male 1 (3.2) 0 (0.0) 0.329
Female 30 (96.8) 29 (100.0)
Race
Caucasian 15 (48.4) 15 (51.7) 0.741
Brown 15 (48.4) 12 (41.4)
Afro-descendent 1 (3.2) 2 (6.9)
Diagnosis time
<5 years 9 (29.0) 7 (24.1) 0.912
5–10 years 14 (45.2) 14 (48.3)
>10 years 8 (25.8) 8 (27.6)
Pre-diagnosis FRy time 3.42 ± 0.99 4.03 ± 1.51 0.731
Disease time after diagnosis 9.16 ± 1.22 9.41 ± 1.00 0.874
Clinical form
Limited 12 (38.7) 14 (48.3) 0.193
Diffuse 14 (45.2) 6 (20.7)
Recent onset 3 (9.7) 4 (13.8)
Overlap 2 (6.5) 5 (17.2)
Monitoring indexes
sHAQ 0.62 ± 0.07 0.66 ± 0.08 0.682
Severity scale 5.26 ± 0.54 4.45 ± 0.51 0.284
Activity scale 2.60 ± 0.27 2.07 ± 0.21 0.136
Skin score 14.06 ± 1.59 12.03 ± 1.37 0.341
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utoimmune diseases, as well as the concept of shared
utoimmunity.39,40
A shared autoimmunity seems to be a critical component
f the genetic basis of autoimmune diseases.39,42,43 Polymor-
hisms in major histocompatibility complex (HLA) have also
een linked to numerous autoimmune diseases such as RA,
pondyloarthritis, and SLE,39,40,43 being of particular interest
he high frequency of HLA-DQA1*0501 in men  with SSc.40
At ﬁrst, it was believed that scleroderma or systemic scle-
osis familial grouping was an uncommon event.44 However,
ubsequently it was demonstrated 1.6% of recurrence of sys-
emic sclerosis in families of SSc patients versus an estimated
isk of only 0.026% in the general population.45 Currently,
t is suggested that a positive family history is the greatest
isk factor ever identiﬁed for development of SSc in a given
ndividual.8,12,40
Likewise, it is well known the high incidence of overlap
yndromes in SSc patients, represented by an association
ith inﬂammatory myopathies, Sjögren’s syndrome, rheuma-
oid arthritis, and systemic lupus erythematosus in these
atients.38,43,46–48
This study conﬁrms the high frequency of polyautoim-
unity (43.3%) and familial autoimmunity (51.7%) in SSc
atients living in the Brazilian Midwest region. Caramaschi
t al.35 found, among 118 SSc patients, 32.2% with one or
wo concomitant autoimmune diseases, with a total of 42 dif-
erent diagnoses. In a larger sample, a study of 719 patientsrequency (relative frequency).
from Canada and Colombia, its authors found 38% of polyau-
toimmunity and 36% of autoimmunity in SSc patients,12
but only ﬁrst-degree relatives of these patients were eval-
uated, which could explain the divergence between the
Canadian/Colombian study and ours.
A more  recent study found, among 121 of 373 (32.4%) fam-
ilies of SSC patients, at least one autoimmune disease in one
or more  ﬁrst-degree relatives.39 It is likely that the percent-
age of familial autoimmunity, much higher on our population
compared to other studies, is due to the fact that we  decided
to extend our search also for ancestors, descendants and col-
laterals to the third degree of kinship.
In our study, the main autoimmune diseases associated
with SSc patients were in agreement with the literature, being
mainly represented by autoimmune thyroiditis, Sjögren’s syn-
drome, and inﬂammatory myopathies.12,35,38,46–48 However,
we found a lower prevalence of rheumatoid arthritis in our
patients, compared to other studies. Probably this occurred
because we  have adopted a stricter criterion for the diagnosis
of an actual overlap with rheumatoid arthritis with the use
of ACR/EULAR17 classiﬁcation criteria for RA, plus the com-
pulsory presence of anti-cyclic citrullinated peptide antibody
(anti-CCP) and/or of typical radiological manifestations of the
disease.As to familial autoimmunity, our data were consistent with
those published in the literature, represented by the observa-
tion of autoimmune thyroiditis, RA, and SLE in SSc patients’
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Table 5 – Autoantibodies in patients with or without
polyautoimmunity.
Variable Polyautoimmunity p-Value
Yes (n = 26) No (n = 34)
Familial autoimmunity
Yes 15 (57.7) 16 (47.1) 0.414
No 11 (42.3) 18 (52.9)
Anti-Ro
Positive 6 (23.1) 1 (2.9) 0.016a
Anti-La
Positive 1 (3.8) 0 (0.0) 0.249
Anti-Sm
Positive 0 (0.0) 1 (2.9) 0.378
Anti-RNP
Positive 5 (19.2) 5 (14.7) 0.641
Anti-Jo 1
Positive 0 (0.0) 2 (5.9) 0.208
Anti-SCL 70
Positive 10 (38.5) 6 (17.6) 0.071
Anti-centromere
Positive 9 (34.6) 16 (47.1) 0.333
Anti-RNA Pol 3
Positive 4 (15.4) 3 (8.8) 0.433
The results are presented as absolute frequency (relative
frequency).
a p-Value in chi-squared test.
Table 6 – Autoantibodies in patients with or without
familial autoimmunity.
Variable Familial autoimmunity p-Value
Yes (n = 31) No (n = 29)
Anti-Ro
Positive 4 (12.9) 3 (10.3) 0.758
Anti-La
Positive 1 (3.2) 0 (0.0) 0.329
Anti-Sm
Positive 0 (0.0) 1 (3.4) 0.297
Anti-RNP
Positive 6 (19.4) 4 (13.8) 0.563
Anti-Jo 1
Positive 1 (3.2) 1 (3.4) 0.962
Anti-SCL 70
Positive 9 (29.0) 7 (24.1) 0.668
Anti-centromere
Positive 9 (29.0) 16 (55.2) 0.040a
Anti-RNA Pol 3
Positive 4 (12.9) 3 (10.3) 0.758
The results are presented as absolute frequency (relative
frequency).
a p-Value in chi-squared test. 0 1 6;5 6(4):314–322
relatives.36,39,42,43 Koumakis et al. found that thyroid autoim-
mune disease and connective tissue diseases (SSc, SLE, SS, RA)
were more  common in families of SSc patients than in families
in the control group.39
With regard to epidemiological data, the only difference
found in the group of polyautoimmunity patients was a longer
duration of the disease after diagnosis. The most plausible
explanation for this ﬁnding would be a diagnosis that occurred
earlier in these carriers with more  than an autoimmune dis-
ease, contributing to their development and survival. Recently,
another Brazilian study conducted by Skare49 stressed that
the knowledge of the coexistence of autoimmune diseases is
vitally important for the correct diagnosis of other autoim-
mune diseases in SSc patients.
We  would expect to ﬁnd a lower quality of life, or a greater
severity/disease activity in polyautoimmunity patients, but
this result did not come true. Actually, the literature describes
the inverse. Avouac et al.,50 for instance, found a milder form
of the disease in patients with the limited form of SSc, and
an association with polyautoimmunity. Caramaschi et al.35
emphasize that the severity of SSc appears to be a risk factor
for development of an additional autoimmune disease.
However, we point out that, in SSc patients and polyau-
toimmunity, there is a likelihood of clinically signiﬁcant
differences when one set apart a particular subgroup of asso-
ciated comorbidities. For example, a recent Brazilian Southern
regional study found a higher frequency of pulmonary hyper-
tension (PH) and a trend of interstitial lung disease in a group
of SSc patients in association with Hashimoto’s thyroiditis
(HT), when compared to patients without HT.49 Taking into
account the 6 cases of PH observed in our SSc patients, we
also found a higher prevalence of PH in those showing an
association with HT (n = 4–66.67%) versus patients without HT
(unpublished data).
These patients were predominantly affected by the limited
form of the disease (57.0% versus 34.6%) and exhibited sig-
niﬁcant features of vascular disease, such as the increased
occurrence of an objective Raynaud’s phenomenon (92.6% ver-
sus 66.7%) and telangiectasia (85.7% versus 68.3%). Our patients
with SSc and HT had a higher incidence of pulmonary ﬁbro-
sis, but this ﬁnding did not reach statistical signiﬁcance (57.1%
versus 45.0%).
Moreover, a large study of 24,728 patients and 55,632 con-
trols found a positive association between history of personal
and familial autoimmune disease with risk of non-Hodgkin’s
lymphoma development, and its authors suggested that the
shared susceptibility can only explain a small fraction of this
increase.37
In this study, the observation of an increased frequency of
anti-Ro in patients with SSc and polyautoimmunity is easily
explained, because the positivity to this antibody was associ-
ated with Sjögren’s syndrome, a very prevalent condition in
this group of patients. On the other hand, the observation of
a lower frequency of anticentromere in patients with familial
autoimmunity was due to the fact that this group of patients
was primarily presenting the diffuse form of the disease, once
again without reaching statistical signiﬁcance. The patients
showing polyautoimmunity and familial autoimmunity were
primarily carriers of the diffuse form of SSc, but this indicator
did not reach statistical signiﬁcance.
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A peculiarity of the city of Campo Grande–MS is that
ts population is basically composed of national and foreign
mmigrants, who  came predominantly from the states of
inas Gerais, Rio Grande do Sul, Parana and Sao Paulo; and
rom countries like Germany, Spain, Italy, Japan, Paraguay, Por-
ugal, Syria and Lebanon.
The main limitation of this study was the small sample of
Sc patients; but with this strategy, we  seek to eliminate the
ain bias observed in large studies of coexistence of autoim-
une diseases, in which the familial autoimmunity history
as provided by the patient, without an independent con-
rmation, or a medical record review. All our SSc patients
re accompanied by the same physician, some of them for
lmost 10 years; and all their family and a large number of
Sc patients’ relatives are followed in other outpatient clinics
t FMUFMS.
It is worth emphasizing the importance of the shared
utoimmunity concept, in order to promote a continuous
urveillance of SSc patients; it is expected that in this scenario
he doctor is able to establish a timely diagnosis of possible
econd or third associated autoimmune disease, or even an
utoimmune disease that is affecting the patient’s relatives.
onclusions
ur SSc patients had a frequency of 43.3% of polyautoimmu-
ity and 51.7% of familiar autoimmunity.
The autoimmune diseases most frequently observed
n polyautoimmunity patients were: Hashimoto’s thyroidi-
is (53.8%), Sjögren’s syndrome (38.5%), and inﬂammatory
yopathy (11.5%). The main autoimmune diseases observed
n of SSc patients’ relatives were: Hashimoto’s thyroiditis
32.3%), rheumatoid arthritis (22.6%), and SLE (22.6%). The
resence of more  than one autoimmune disease in SSc
atients did not correlate with disease severity or activity.
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